CFTR and cystic fibrosis: A study on homozygous F508del-CFTR mice reinforced the hypothesis that the F508del-CFTR mutation may contribute to bone disease by delaying new bone formation in infants and young children with cystic fibrosis, suggesting that CFTR-targeted treatments could be a valuable tool in the bone health of CF patients [21].